Surgery Partners Eyes Profit Turnaround Amid Persistent Losses

Forward-Looking Analysis

Analysts project Surgery Partners (SGRY) to report earnings per share (EPS) of $0.06 for the 2026 Q2 period. This represents a significant turnaround from the previous quarter's EPS of -$0.12 and the market expectation of -$0.28, indicating a return to profitability. Revenue is forecasted at $830.37 million, suggesting a sequential increase from the prior quarter's $810.90 million. The consensus among 12 analysts, who predominantly maintain a "Buy" rating, points to a positive trajectory despite recent volatility. The average price target stands at $28.00, with a high of $36.00 and a low of $18.00, implying a potential upside of approximately 22.04% from the current trading price of $15.533. The earnings forecast score of 8.00 ranks the company 29th out of 74 in the Healthcare Providers & Services industry. While the company has faced pressure from staffing issues and past net losses, the current quarter's estimates reflect an expectation of stabilized operations and improved financial metrics.

Historical Performance Review

Surgery Partners delivered mixed results in 2026 Q1, reporting revenue of $810.90 million and a gross profit of $160.20 million. However, the bottom line remained under pressure, with a net income loss of $2.10 million and an EPS of -$0.28. This performance highlighted ongoing challenges in managing costs relative to revenue growth, setting a low baseline for the upcoming Q2 report where analysts anticipate a return to positive earnings per share.

Additional News

Surgery Partners recently faced significant market pressure after its third-quarter results missed profit expectations, causing shares to decline. Adjusted earnings came in at $0.19 per share, falling short of the Wall Street target of $0.25, while net losses widened to $31.7 million from $4.9 million a year prior. Despite this negative reaction, the company demonstrated steady revenue growth, signaling solid demand for outpatient procedures. For long-term investors, this growth suggests potential for improving margins and gradual earnings recovery. However, persistent net losses continue to constrain the company's ability to strengthen its balance sheet, reinvest in growth, or return capital to shareholders. Current technical sentiment signals a "Sell," and the stock has held near support levels amid these quiet but concerning fundamentals.

Summary & Outlook

Surgery Partners exhibits a fragile financial health marked by recent net losses but showing signs of stabilization. The primary growth catalyst is steady demand for outpatient procedures, which supports revenue expansion. However, the risk remains elevated due to persistent net losses and staffing pressures that hinder balance sheet strength and capital return capabilities. With Q2 EPS expected to turn positive at $0.06 and revenue projected to rise, the outlook is cautiously neutral. While the return to profitability is a positive step, the company must demonstrate sustained margin improvement to overcome the overhang of previous losses and achieve a fully bullish stance.